New Report Gives Boost to Provenge Ahead of CMS Review Meeting

As the Centers for Medicare & Medicaid Services (CMS) prepares to consider the evidence for extending coverage to Dendreon’s prostate cancer drug Provenge, an independent review has failed to raise red flags about its effectiveness. While the report conducted for the Agency for Healthcare Research and Quality labeled the strength of the evidence supporting Provenge’s (sipuleucel-T) approval as “moderate,” it ultimately did not question the FDA’s endorsement of the drug.
Drug Industry Daily